Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...

Cleveland Clinic researchers have found that nearly two-thirds of patients with HER2-positive metastatic breast cancer did ...

Precision medicine in endometrial cancer emphasizes molecular drivers, challenging traditional histopathologic approaches and ...

Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, ...

OS Animal Health (OSAH), a wholly owned OS Therapies (OSTX) subsidiary, targets an IPO on NYSE American or Nasdaq ...

Advanced gastroesophageal adenocarcinoma (GEA) with HER2 positivity has long presented significant treatment challenges, with ...

OS Therapies’ HER2-focused immunotherapy prevented patients’ lung cancer from returning in 33% of cases, hitting the primary goal of a phase 2 trial. The therapy, dubbed OST-HER2, uses a ...

I'll be presenting a poster discussion on low HER2. The title is "Are We Splitting HERs?" -- a pun on hairs. But splitting is because the new drugs, the ADC [antibody-drug conjugate] trastuzumab ...

This symposium took place during the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The aim ...

The approval is supported by data from the DESTINY-Gastric04 Phase III trial.

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...